Hengrui Pharmaceutical (600276.SH) issued an announcement. Recently, the company's subsidiaries Shanghai Hengrui Pharmaceutical Co., Ltd. and Shandong...
Zhitong Finance App News, Hengrui Pharmaceutical (600276.SH) issued an announcement. Recently, the company's subsidiaries Shanghai Hengrui Pharmaceutical Co., Ltd. and Shandong Shengdi Pharmaceutical Co., Ltd. received approval from the State Drug Administration to issue a “Drug Clinical Trial Approval Notice” for HRS-6208 capsules, which will conduct clinical trials in patients with solid tumors in the near future.
HRS-6208 is a novel, highly effective, and selective small-molecule inhibitor that can effectively and selectively inhibit phosphorylation activation of targets, affect cell cycle and transcriptional activity, thereby inhibiting tumor cell proliferation and exhibiting anti-tumor effects. According to inquiries, there are currently no similar products approved for sale at home or abroad. Up to now, HRS-6208 capsule-related projects have invested a total of about 23.78 million yuan in R&D costs.
